Rocket One Inc. Deferred Income Tax Expense (Benefit)
Rocket One Inc. (RKTO) reported Deferred Income Tax Expense (Benefit) of $1.49 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2021-03-16
- Rocket One Inc. deferred income tax expense (benefit) for fiscal 2020 was $1.49M, a 11.72% decline from fiscal 2019.
- Rocket One Inc. deferred income tax expense (benefit) for fiscal 2019 was $1.69M, a 303.74% increase from fiscal 2018.
- Rocket One Inc. deferred income tax expense (benefit) for fiscal 2018 was $417.78K.
| Period end | Deferred Income Tax Expense (Benefit) 8 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2020-12-31 | $1.49M 10-K · filed 2021-03-16 | ||
| 2019-12-31 | $1.69M 10-K · filed 2021-03-16 | $1.69M 10-K · filed 2020-03-02 | |
| 2018-12-31 | $417.78K 10-K · filed 2020-03-02 | ||
| 2017-12-31 | $425.39K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |